CMS approves Massachusetts’ transition to ACO model for Medicaid

A five-year, $52.5 billion Medicaid waiver for Massachusetts has been approved by CMS, allowing the state to reorganize its MassHealth program.

The overhaul will include transitioning the program to an accountable care organization (ACO) model, while offering ACOs and community health groups $1.8 billion in incentives for improvements in care integration and outcomes for behavioral health and long-term services and supports.

“Our administration is pleased to announce this innovative waiver as a major step toward creating a sustainable MassHealth system for the people of the Commonwealth,” Massachusetts Gov. Charlie Baker said in a statement.  “This waiver is the first major overhaul of the MassHealth program in 20 years and includes critical reforms to promote coordinated care, hold providers accountable and offer expanded access for substance abuse disorder services driven by the opioid crisis.”

Massachusetts’ previous five-year waiver was due to expire in July 2017. The new deal prevents the state from losing $1 billion in federal funds for the 1.9 million people served by MassHealth.

“We’re excited to approve this innovative Medicaid waiver, which is another step forward in the American healthcare system’s shift toward value. This waiver will allow MassHealth to partner with provider-led care delivery organizations to deliver quality, patient-centered care to Medicaid beneficiaries,” said HHS Secretary Sylvia M. Burwell.

Among the goals of the new waiver will be “near universal health coverage” among Massachusetts residents. The state has one of the highest insured rates, though 2 percent of its population remains uncovered despite an individual mandate being in place since 2006.

There’s also help for safety-net hospitals in the waiver, as the number of facilities eligible for uncompensated care payments from CMS will be doubled from seven to 15. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.